Table 5.

Univariate and Multivariate Competing Risks Analyses of Predictors of Dropout in the control group

Univariate Analysis
Predictor Variables	Sub-Hazard ratio (95% CI)	P-value
Diagnosis of Liver Disease
HBV (vs. HCV)	0.79 (0.51–1.22)	0.29
Others (vs. HCV)	0.80 (0.46–1.38)	0.42
Child’s class cirrhosis
B (vs. A)	1.26 (0.86–1.84)	0.23
C (vs. A)	1.51 (0.84–2.70)	0.17
AFP
≥ 100 (vs. < 100)	2.28 (1.59–3.25)	<0.001
≥ 300 (vs. < 300)	2.37 (1.59–3.52)	<0.001
≥ 400 (vs. < 400)	3.09 (2.07–4.60)	<0.001
≥ 500 (vs. < 500)	3.25 (2.16–4.89)	<0.001
≥ 1000 (vs. < 1000)	2.43 (1.48–3.98)	<0.001
Types of LRT
TACE (vs. RFA)	0.83 (0.43–1.60)	0.57
Combination Treatment (vs. RFA)	1.26 (0.66–2.41)	0.48
Number of lesions
2 (vs. 1)	1.09 (0.70–1.70)	0.70
3 (vs. 1)	3.45 (2.18–5.46)	<0.001
4 (vs. 1)	NA	NA
5 (vs. 1)	NA	NA
Diameter of largest lesion (per 1 cm increase)	1.30 (1.07–1.58)	0.009
Multivariate Analysis:
Predictor Variables	Hazard ratio (95% CI)	P-value
AFP ≥ 1000 ng/mL	1.85 (1.11–3.07)	0.02
Number of lesions
2 (vs. 1)	1.71 (1.04–2.81)	0.04
3 (vs. 1)	5.67 (3.26–9.86)	<0.001
Diameter of largest lesion (per 1 cm increase)	1.70 (1.35–2.13)	<0.001

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; LRT, local regional therapy; TACE, transarterial chemoembolization; RFA, radiofrequency ablation.